The approval last year in the EU of generic Remicade represents a milestone of sorts. Biosimilars aim to replace, or at least compete with, products that generated over $100 billion in worldwide sales in 2013. While Europe has led the way in the development of a regulatory pathway for the…
As a strategy to offset declining revenues, companies are testing a variety of initiatives focused on creating value added services (VAS) for drugs and medical devices. Disease management programs have been tried before by product manufacturers with limited success. This new wave differs from prior experiments in that it leverages…
In today’s global market environment, payers are looking hard to reduce reimbursement and resist paying for incremental product enhancements. On top of that, manufacturers’ revenue streams continue to be threatened by looming patent expiration dates and the simultaneous influx of generic competition. What actions should companies consider taking to protect…
With the cost of cancer care set to continue to spiral, manufacturers must understand and adapt to the new access and reimbursement landscape in order to ensure the success of their oncology pipelines. That’s why eyeforpharma partnered with Numerof & Associates to produce an authoritative whitepaper that frames the changing dynamics in…
After seeing their products being rejected in recent years by reimbursement agencies overseas, pharmaceutical manufacturers are suffering the same fate in the U.S., as PBMs refuse to include a growing list of drugs on their formularies. The country’s largest PBM, Express Scripts, recently announced that 48 products, including a range…
As the rules for success change, pharmaceutical and medical device companies must rethink their approach to the market. One critical element that requires transformation is product positioning. Historically, a product’s ‘value’ was determined by clinicians as they made decisions about which products to use for their patients. Yet, there is…
